Related Experiment Videos
Letter to the Editor from Colle et al
Raphael Colle1, Thierry Andre2, Yves Menu3
1Sorbonne Université and Hospital Saint Antoine, Department of Medical Oncology, AP-HP, Paris, France.
Journal for Immunotherapy of Cancer
|June 24, 2021
Summary
Pseudoprogression (PSPD) occurs in 10% of metastatic colorectal cancer patients treated with immune checkpoint inhibitors (ICI). Early imaging and iRECIST criteria are crucial for accurate assessment and avoiding premature treatment cessation.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Immune checkpoint inhibitors (ICI) show promise in treating metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR).
- Early tumor shrinkage and depth of response are known prognostic indicators in this patient group.
- The phenomenon of pseudoprogression (PSPD) has been observed in patients receiving ICI therapy for MSI/dMMR mCRC.